A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2013-09

AUTHORS

Dana E. Rathkopf, Joel Picus, Arif Hussain, Susan Ellard, Kim Nguyen Chi, Thomas Nydam, Erin Allen-Freda, Kaushal Kishor Mishra, Maria Grazia Porro, Howard I. Scher, George Wilding

ABSTRACT

PURPOSE: Panobinostat, a pan-deacetylase inhibitor, increases acetylation of proteins associated with growth and survival of malignant cells. This phase 2 study evaluated the efficacy of intravenous (IV) panobinostat in patients with castration-resistant prostate cancer (CRPC) who had previously received chemotherapy. The primary end point was 24-week progression-free survival. Secondary end points included safety, tolerability, and the proportion of patients with a prostate-specific antigen (PSA) decline. METHODS: IV panobinostat (20 mg/m(2)) was administered to patients on days 1 and 8 of a 21-day cycle. Tumor response was assessed by imaging every 12 weeks (4 cycles) according to modified response evaluation criteria in solid tumors (Scher et al. in Clin Cancer Res 11:5223-5232, 23), and PSA response was defined as a 50 % decrease from baseline maintained for ≥4 weeks. Safety monitoring was routinely performed and included electrocardiogram monitoring. RESULTS: Of 35 enrolled patients, four (11.4 %) were alive without progression of disease at 24 weeks. PSA was evaluated in 34 (97.1 %) patients: five (14.3 %) patients demonstrated a decrease in PSA but none ≥50 %; one patient (2.9 %) had carcinoembryonic antigen as a marker of his prostate cancer, which declined by 43 %. Toxicities regardless of relationship to panobinostat included fatigue (62.9 %), thrombocytopenia (45.7 %), nausea (51.4 %), and decreased appetite (37.1 %). CONCLUSIONS: Despite promising preclinical data and scientific rationale, treatment with IV panobinostat did not show a sufficient level of clinical activity to pursue further investigation as a single agent in CRPC. More... »

PAGES

537-544

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-013-2224-8

DOI

http://dx.doi.org/10.1007/s00280-013-2224-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1017758793

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/23820963


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Histone Deacetylase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hydroxamic Acids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Indoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infusions, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Orchiectomy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostate-Specific Antigen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostatic Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Memorial Sloan Kettering Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Memorial Sloan-Kettering Cancer Center, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rathkopf", 
        "givenName": "Dana E.", 
        "id": "sg:person.01106075135.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01106075135.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Washington University in St. Louis", 
          "id": "https://www.grid.ac/institutes/grid.4367.6", 
          "name": [
            "Siteman Cancer Center, Barnes-Jewish Hospital, Washington University School of Medicine, St. Louis, MO, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Picus", 
        "givenName": "Joel", 
        "id": "sg:person.0752503711.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752503711.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hussain", 
        "givenName": "Arif", 
        "id": "sg:person.01135457735.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01135457735.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "BC Cancer Agency", 
          "id": "https://www.grid.ac/institutes/grid.248762.d", 
          "name": [
            "British Columbia Cancer Agency, Kelowna, BC, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ellard", 
        "givenName": "Susan", 
        "id": "sg:person.01004224136.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01004224136.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "BC Cancer Agency", 
          "id": "https://www.grid.ac/institutes/grid.248762.d", 
          "name": [
            "British Columbia Cancer Agency, Vancouver, BC, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chi", 
        "givenName": "Kim Nguyen", 
        "id": "sg:person.01142252161.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142252161.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418424.f", 
          "name": [
            "Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nydam", 
        "givenName": "Thomas", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418424.f", 
          "name": [
            "Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Allen-Freda", 
        "givenName": "Erin", 
        "id": "sg:person.012275634715.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012275634715.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418424.f", 
          "name": [
            "Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mishra", 
        "givenName": "Kaushal Kishor", 
        "id": "sg:person.01116567352.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01116567352.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Pharma AG, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Porro", 
        "givenName": "Maria Grazia", 
        "id": "sg:person.0671136741.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0671136741.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Memorial Sloan Kettering Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Memorial Sloan-Kettering Cancer Center, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Scher", 
        "givenName": "Howard I.", 
        "id": "sg:person.01060421735.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01060421735.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Wisconsin\u2013Madison", 
          "id": "https://www.grid.ac/institutes/grid.14003.36", 
          "name": [
            "Paul P. Carbone Cancer Center, University of Wisconsin, Madison, WI, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wilding", 
        "givenName": "George", 
        "id": "sg:person.016113722177.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016113722177.62"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.3390/ph3092751", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000403597"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/emboj/19.4.662", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001936972"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/mcb.23.23.8563-8575.2003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003600906"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2217/fon.09.36", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006149341"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-06-3093", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006258831"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc2887", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006993157", 
          "https://doi.org/10.1038/nrc2887"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.18.9159", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008720167"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-07-2057", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011079005"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3816/cgc.2005.n.015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012400722"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1014618", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018044872"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1208833", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019291778", 
          "https://doi.org/10.1038/sj.onc.1208833"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1208833", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019291778", 
          "https://doi.org/10.1038/sj.onc.1208833"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1208833", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019291778", 
          "https://doi.org/10.1038/sj.onc.1208833"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-010-1289-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021855880", 
          "https://doi.org/10.1007/s00280-010-1289-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-010-1289-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021855880", 
          "https://doi.org/10.1007/s00280-010-1289-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-05-0109", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027547437"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/pros.20673", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028656990"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.canlet.2009.02.019", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028927359"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.24597", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030320408"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.24597", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030320408"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature03672", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030798307", 
          "https://doi.org/10.1038/nature03672"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature03672", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030798307", 
          "https://doi.org/10.1038/nature03672"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.12.4487", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031178629"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/92.3.205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032301848"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-08-2787", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033328549"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1155/2011/580318", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033372709"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1074/jbc.m512719200", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034710442"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1207506", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044642614"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1006/bbrc.2001.5639", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047128510"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-08-2216", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048751420"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/pros.21051", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050109720"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/pros.21051", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050109720"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6604199", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052387252", 
          "https://doi.org/10.1038/sj.bjc.6604199"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1038/aja.2009.81", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1056439625"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1038/aja.2009.81", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1056439625"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4161/epi.3.6.7273", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072302870"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.11.3461", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074545753"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074708142", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2013-09", 
    "datePublishedReg": "2013-09-01", 
    "description": "PURPOSE: Panobinostat, a pan-deacetylase inhibitor, increases acetylation of proteins associated with growth and survival of malignant cells. This phase 2 study evaluated the efficacy of intravenous (IV) panobinostat in patients with castration-resistant prostate cancer (CRPC) who had previously received chemotherapy. The primary end point was 24-week progression-free survival. Secondary end points included safety, tolerability, and the proportion of patients with a prostate-specific antigen (PSA) decline.\nMETHODS: IV panobinostat (20\u00a0mg/m(2)) was administered to patients on days 1 and 8 of a 21-day cycle. Tumor response was assessed by imaging every 12\u00a0weeks (4 cycles) according to modified response evaluation criteria in solid tumors (Scher et al. in Clin Cancer Res 11:5223-5232, 23), and PSA response was defined as a 50\u00a0% decrease from baseline maintained for \u22654\u00a0weeks. Safety monitoring was routinely performed and included electrocardiogram monitoring.\nRESULTS: Of 35 enrolled patients, four (11.4\u00a0%) were alive without progression of disease at 24\u00a0weeks. PSA was evaluated in 34 (97.1\u00a0%) patients: five (14.3\u00a0%) patients demonstrated a decrease in PSA but none \u226550\u00a0%; one patient (2.9\u00a0%) had carcinoembryonic antigen as a marker of his prostate cancer, which declined by 43\u00a0%. Toxicities regardless of relationship to panobinostat included fatigue (62.9\u00a0%), thrombocytopenia (45.7\u00a0%), nausea (51.4\u00a0%), and decreased appetite (37.1\u00a0%).\nCONCLUSIONS: Despite promising preclinical data and scientific rationale, treatment with IV panobinostat did not show a sufficient level of clinical activity to pursue further investigation as a single agent in CRPC.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00280-013-2224-8", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.7143909", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2438793", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2438809", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.7144010", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "72"
      }
    ], 
    "name": "A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer", 
    "pagination": "537-544", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "549d4c70e11fb3ae41733604c96ac5a1b4345496a8ab2666d7928e500b387e78"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "23820963"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7806519"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-013-2224-8"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1017758793"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-013-2224-8", 
      "https://app.dimensions.ai/details/publication/pub.1017758793"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T19:57", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8681_00000511.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs00280-013-2224-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-013-2224-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-013-2224-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-013-2224-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-013-2224-8'


 

This table displays all metadata directly associated to this object as RDF triples.

321 TRIPLES      21 PREDICATES      75 URIs      36 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-013-2224-8 schema:about N2b68df1641ef43ccbeab2e0045e72f0e
2 N35ea30d0d98d4d28b5ef45d8b4193565
3 N4bacafbfe5c14279b27ac627b7696420
4 N757b2de03a53495085f7155c9d1e0f13
5 N795e464a689e45dd8d8adb97fd42a99d
6 N858f2fc5bd0145c2aea311bee38690eb
7 N8b4205c9988a4e1882cca8186a644e90
8 Na52ca26aa10344f086e8edb836a3544f
9 Na708969cd71344cfbe3403265eb6cedc
10 Nc7d27b023d4c42f6a3d7d6202f9c13b4
11 Ncb110227d2364ec298dd6abec457056e
12 Ndc2d14c9baf84d72ab248a1a2a0fdb83
13 Ne925cd7a711f40478ea889c680b096b0
14 Nf5fdd192f22c413a943020cacec453b2
15 Nfc0ba6af90714d76a38eac7812353d0b
16 anzsrc-for:11
17 anzsrc-for:1112
18 schema:author Nba045921bf0a419ab619549c6031564b
19 schema:citation sg:pub.10.1007/s00280-010-1289-x
20 sg:pub.10.1038/nature03672
21 sg:pub.10.1038/nrc2887
22 sg:pub.10.1038/sj.bjc.6604199
23 sg:pub.10.1038/sj.onc.1208833
24 https://app.dimensions.ai/details/publication/pub.1074708142
25 https://doi.org/10.1002/cncr.24597
26 https://doi.org/10.1002/pros.20673
27 https://doi.org/10.1002/pros.21051
28 https://doi.org/10.1006/bbrc.2001.5639
29 https://doi.org/10.1016/j.canlet.2009.02.019
30 https://doi.org/10.1038/aja.2009.81
31 https://doi.org/10.1056/nejmoa1014618
32 https://doi.org/10.1056/nejmoa1207506
33 https://doi.org/10.1074/jbc.m512719200
34 https://doi.org/10.1093/emboj/19.4.662
35 https://doi.org/10.1093/jnci/92.3.205
36 https://doi.org/10.1128/mcb.23.23.8563-8575.2003
37 https://doi.org/10.1155/2011/580318
38 https://doi.org/10.1158/0008-5472.can-07-2057
39 https://doi.org/10.1158/0008-5472.can-08-2216
40 https://doi.org/10.1158/1078-0432.ccr-05-0109
41 https://doi.org/10.1158/1078-0432.ccr-06-3093
42 https://doi.org/10.1158/1078-0432.ccr-08-2787
43 https://doi.org/10.1200/jco.1999.17.11.3461
44 https://doi.org/10.1200/jco.2007.12.4487
45 https://doi.org/10.1200/jco.2008.18.9159
46 https://doi.org/10.2217/fon.09.36
47 https://doi.org/10.3390/ph3092751
48 https://doi.org/10.3816/cgc.2005.n.015
49 https://doi.org/10.4161/epi.3.6.7273
50 schema:datePublished 2013-09
51 schema:datePublishedReg 2013-09-01
52 schema:description PURPOSE: Panobinostat, a pan-deacetylase inhibitor, increases acetylation of proteins associated with growth and survival of malignant cells. This phase 2 study evaluated the efficacy of intravenous (IV) panobinostat in patients with castration-resistant prostate cancer (CRPC) who had previously received chemotherapy. The primary end point was 24-week progression-free survival. Secondary end points included safety, tolerability, and the proportion of patients with a prostate-specific antigen (PSA) decline. METHODS: IV panobinostat (20 mg/m(2)) was administered to patients on days 1 and 8 of a 21-day cycle. Tumor response was assessed by imaging every 12 weeks (4 cycles) according to modified response evaluation criteria in solid tumors (Scher et al. in Clin Cancer Res 11:5223-5232, 23), and PSA response was defined as a 50 % decrease from baseline maintained for ≥4 weeks. Safety monitoring was routinely performed and included electrocardiogram monitoring. RESULTS: Of 35 enrolled patients, four (11.4 %) were alive without progression of disease at 24 weeks. PSA was evaluated in 34 (97.1 %) patients: five (14.3 %) patients demonstrated a decrease in PSA but none ≥50 %; one patient (2.9 %) had carcinoembryonic antigen as a marker of his prostate cancer, which declined by 43 %. Toxicities regardless of relationship to panobinostat included fatigue (62.9 %), thrombocytopenia (45.7 %), nausea (51.4 %), and decreased appetite (37.1 %). CONCLUSIONS: Despite promising preclinical data and scientific rationale, treatment with IV panobinostat did not show a sufficient level of clinical activity to pursue further investigation as a single agent in CRPC.
53 schema:genre research_article
54 schema:inLanguage en
55 schema:isAccessibleForFree true
56 schema:isPartOf N5bbcf9a976b64816b9f85a1fb931c743
57 Nc1d17071fed2494ab3e320dc9ca1361a
58 sg:journal.1088364
59 schema:name A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer
60 schema:pagination 537-544
61 schema:productId N56b0e541b74a41e69b0135e6f47fdabc
62 N6557a8cb991e42e4bcda466f1e406dbf
63 N871fe5ae5c734668bbd4b8f96d51ffc4
64 Nb5080c7b63e543139872c9236db8ff9d
65 Nc2fba665ddb74318b3f7304870a21b9c
66 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017758793
67 https://doi.org/10.1007/s00280-013-2224-8
68 schema:sdDatePublished 2019-04-10T19:57
69 schema:sdLicense https://scigraph.springernature.com/explorer/license/
70 schema:sdPublisher N2d2dc71c7aad4c8b9058dec5afa4baaa
71 schema:url http://link.springer.com/10.1007%2Fs00280-013-2224-8
72 sgo:license sg:explorer/license/
73 sgo:sdDataset articles
74 rdf:type schema:ScholarlyArticle
75 N2124cdea910c408992212e690dc1a3f5 rdf:first sg:person.01116567352.06
76 rdf:rest N6f4fce0da9484a0282bdab275125b6bb
77 N22f62ce3f7ba4410bde2b0dab25cd692 rdf:first sg:person.01135457735.37
78 rdf:rest Nd1c54939088b4c0eb8998d7ddfbc9a11
79 N290bd7fb64f5484f8bc252aac7770300 rdf:first sg:person.012275634715.41
80 rdf:rest N2124cdea910c408992212e690dc1a3f5
81 N2b68df1641ef43ccbeab2e0045e72f0e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
82 schema:name Treatment Outcome
83 rdf:type schema:DefinedTerm
84 N2d2dc71c7aad4c8b9058dec5afa4baaa schema:name Springer Nature - SN SciGraph project
85 rdf:type schema:Organization
86 N35ea30d0d98d4d28b5ef45d8b4193565 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Infusions, Intravenous
88 rdf:type schema:DefinedTerm
89 N363eddaa04184b7ab9666754f774ee4f rdf:first sg:person.0752503711.41
90 rdf:rest N22f62ce3f7ba4410bde2b0dab25cd692
91 N4bacafbfe5c14279b27ac627b7696420 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Male
93 rdf:type schema:DefinedTerm
94 N56b0e541b74a41e69b0135e6f47fdabc schema:name readcube_id
95 schema:value 549d4c70e11fb3ae41733604c96ac5a1b4345496a8ab2666d7928e500b387e78
96 rdf:type schema:PropertyValue
97 N5bbcf9a976b64816b9f85a1fb931c743 schema:issueNumber 3
98 rdf:type schema:PublicationIssue
99 N6557a8cb991e42e4bcda466f1e406dbf schema:name nlm_unique_id
100 schema:value 7806519
101 rdf:type schema:PropertyValue
102 N6f4fce0da9484a0282bdab275125b6bb rdf:first sg:person.0671136741.48
103 rdf:rest Nc37f6a2330af4e84b45b6b8adb13c5cb
104 N757b2de03a53495085f7155c9d1e0f13 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Prostate-Specific Antigen
106 rdf:type schema:DefinedTerm
107 N795e464a689e45dd8d8adb97fd42a99d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Humans
109 rdf:type schema:DefinedTerm
110 N7db0f2de6cc2495cae732d0ad6046c51 rdf:first Nfd554aad96f44e9a9d8c55b633bf1643
111 rdf:rest N290bd7fb64f5484f8bc252aac7770300
112 N858f2fc5bd0145c2aea311bee38690eb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Hydroxamic Acids
114 rdf:type schema:DefinedTerm
115 N871fe5ae5c734668bbd4b8f96d51ffc4 schema:name pubmed_id
116 schema:value 23820963
117 rdf:type schema:PropertyValue
118 N8b4205c9988a4e1882cca8186a644e90 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Aged, 80 and over
120 rdf:type schema:DefinedTerm
121 N8e3f237229ea4cb4b03a8c46fa8f8b9d rdf:first sg:person.01142252161.65
122 rdf:rest N7db0f2de6cc2495cae732d0ad6046c51
123 Na52ca26aa10344f086e8edb836a3544f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Middle Aged
125 rdf:type schema:DefinedTerm
126 Na708969cd71344cfbe3403265eb6cedc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Indoles
128 rdf:type schema:DefinedTerm
129 Nb5080c7b63e543139872c9236db8ff9d schema:name doi
130 schema:value 10.1007/s00280-013-2224-8
131 rdf:type schema:PropertyValue
132 Nba045921bf0a419ab619549c6031564b rdf:first sg:person.01106075135.47
133 rdf:rest N363eddaa04184b7ab9666754f774ee4f
134 Nc1d17071fed2494ab3e320dc9ca1361a schema:volumeNumber 72
135 rdf:type schema:PublicationVolume
136 Nc2fba665ddb74318b3f7304870a21b9c schema:name dimensions_id
137 schema:value pub.1017758793
138 rdf:type schema:PropertyValue
139 Nc37f6a2330af4e84b45b6b8adb13c5cb rdf:first sg:person.01060421735.36
140 rdf:rest Ne12380abb4cb4a34adf70b436ee44a1f
141 Nc7d27b023d4c42f6a3d7d6202f9c13b4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Histone Deacetylase Inhibitors
143 rdf:type schema:DefinedTerm
144 Ncb110227d2364ec298dd6abec457056e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Aged
146 rdf:type schema:DefinedTerm
147 Nd1c54939088b4c0eb8998d7ddfbc9a11 rdf:first sg:person.01004224136.10
148 rdf:rest N8e3f237229ea4cb4b03a8c46fa8f8b9d
149 Nd9ee3038956548399e338b3af711dae5 schema:name Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA
150 rdf:type schema:Organization
151 Ndc2d14c9baf84d72ab248a1a2a0fdb83 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Orchiectomy
153 rdf:type schema:DefinedTerm
154 Ne12380abb4cb4a34adf70b436ee44a1f rdf:first sg:person.016113722177.62
155 rdf:rest rdf:nil
156 Ne925cd7a711f40478ea889c680b096b0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Antineoplastic Agents
158 rdf:type schema:DefinedTerm
159 Nf5fdd192f22c413a943020cacec453b2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Prostatic Neoplasms
161 rdf:type schema:DefinedTerm
162 Nfc0ba6af90714d76a38eac7812353d0b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Disease-Free Survival
164 rdf:type schema:DefinedTerm
165 Nfd554aad96f44e9a9d8c55b633bf1643 schema:affiliation https://www.grid.ac/institutes/grid.418424.f
166 schema:familyName Nydam
167 schema:givenName Thomas
168 rdf:type schema:Person
169 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
170 schema:name Medical and Health Sciences
171 rdf:type schema:DefinedTerm
172 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
173 schema:name Oncology and Carcinogenesis
174 rdf:type schema:DefinedTerm
175 sg:grant.2438793 http://pending.schema.org/fundedItem sg:pub.10.1007/s00280-013-2224-8
176 rdf:type schema:MonetaryGrant
177 sg:grant.2438809 http://pending.schema.org/fundedItem sg:pub.10.1007/s00280-013-2224-8
178 rdf:type schema:MonetaryGrant
179 sg:grant.7143909 http://pending.schema.org/fundedItem sg:pub.10.1007/s00280-013-2224-8
180 rdf:type schema:MonetaryGrant
181 sg:grant.7144010 http://pending.schema.org/fundedItem sg:pub.10.1007/s00280-013-2224-8
182 rdf:type schema:MonetaryGrant
183 sg:journal.1088364 schema:issn 0344-5704
184 1432-0843
185 schema:name Cancer Chemotherapy and Pharmacology
186 rdf:type schema:Periodical
187 sg:person.01004224136.10 schema:affiliation https://www.grid.ac/institutes/grid.248762.d
188 schema:familyName Ellard
189 schema:givenName Susan
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01004224136.10
191 rdf:type schema:Person
192 sg:person.01060421735.36 schema:affiliation https://www.grid.ac/institutes/grid.51462.34
193 schema:familyName Scher
194 schema:givenName Howard I.
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01060421735.36
196 rdf:type schema:Person
197 sg:person.01106075135.47 schema:affiliation https://www.grid.ac/institutes/grid.51462.34
198 schema:familyName Rathkopf
199 schema:givenName Dana E.
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01106075135.47
201 rdf:type schema:Person
202 sg:person.01116567352.06 schema:affiliation https://www.grid.ac/institutes/grid.418424.f
203 schema:familyName Mishra
204 schema:givenName Kaushal Kishor
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01116567352.06
206 rdf:type schema:Person
207 sg:person.01135457735.37 schema:affiliation Nd9ee3038956548399e338b3af711dae5
208 schema:familyName Hussain
209 schema:givenName Arif
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01135457735.37
211 rdf:type schema:Person
212 sg:person.01142252161.65 schema:affiliation https://www.grid.ac/institutes/grid.248762.d
213 schema:familyName Chi
214 schema:givenName Kim Nguyen
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142252161.65
216 rdf:type schema:Person
217 sg:person.012275634715.41 schema:affiliation https://www.grid.ac/institutes/grid.418424.f
218 schema:familyName Allen-Freda
219 schema:givenName Erin
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012275634715.41
221 rdf:type schema:Person
222 sg:person.016113722177.62 schema:affiliation https://www.grid.ac/institutes/grid.14003.36
223 schema:familyName Wilding
224 schema:givenName George
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016113722177.62
226 rdf:type schema:Person
227 sg:person.0671136741.48 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
228 schema:familyName Porro
229 schema:givenName Maria Grazia
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0671136741.48
231 rdf:type schema:Person
232 sg:person.0752503711.41 schema:affiliation https://www.grid.ac/institutes/grid.4367.6
233 schema:familyName Picus
234 schema:givenName Joel
235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752503711.41
236 rdf:type schema:Person
237 sg:pub.10.1007/s00280-010-1289-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1021855880
238 https://doi.org/10.1007/s00280-010-1289-x
239 rdf:type schema:CreativeWork
240 sg:pub.10.1038/nature03672 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030798307
241 https://doi.org/10.1038/nature03672
242 rdf:type schema:CreativeWork
243 sg:pub.10.1038/nrc2887 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006993157
244 https://doi.org/10.1038/nrc2887
245 rdf:type schema:CreativeWork
246 sg:pub.10.1038/sj.bjc.6604199 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052387252
247 https://doi.org/10.1038/sj.bjc.6604199
248 rdf:type schema:CreativeWork
249 sg:pub.10.1038/sj.onc.1208833 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019291778
250 https://doi.org/10.1038/sj.onc.1208833
251 rdf:type schema:CreativeWork
252 https://app.dimensions.ai/details/publication/pub.1074708142 schema:CreativeWork
253 https://doi.org/10.1002/cncr.24597 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030320408
254 rdf:type schema:CreativeWork
255 https://doi.org/10.1002/pros.20673 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028656990
256 rdf:type schema:CreativeWork
257 https://doi.org/10.1002/pros.21051 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050109720
258 rdf:type schema:CreativeWork
259 https://doi.org/10.1006/bbrc.2001.5639 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047128510
260 rdf:type schema:CreativeWork
261 https://doi.org/10.1016/j.canlet.2009.02.019 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028927359
262 rdf:type schema:CreativeWork
263 https://doi.org/10.1038/aja.2009.81 schema:sameAs https://app.dimensions.ai/details/publication/pub.1056439625
264 rdf:type schema:CreativeWork
265 https://doi.org/10.1056/nejmoa1014618 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018044872
266 rdf:type schema:CreativeWork
267 https://doi.org/10.1056/nejmoa1207506 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044642614
268 rdf:type schema:CreativeWork
269 https://doi.org/10.1074/jbc.m512719200 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034710442
270 rdf:type schema:CreativeWork
271 https://doi.org/10.1093/emboj/19.4.662 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001936972
272 rdf:type schema:CreativeWork
273 https://doi.org/10.1093/jnci/92.3.205 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032301848
274 rdf:type schema:CreativeWork
275 https://doi.org/10.1128/mcb.23.23.8563-8575.2003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003600906
276 rdf:type schema:CreativeWork
277 https://doi.org/10.1155/2011/580318 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033372709
278 rdf:type schema:CreativeWork
279 https://doi.org/10.1158/0008-5472.can-07-2057 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011079005
280 rdf:type schema:CreativeWork
281 https://doi.org/10.1158/0008-5472.can-08-2216 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048751420
282 rdf:type schema:CreativeWork
283 https://doi.org/10.1158/1078-0432.ccr-05-0109 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027547437
284 rdf:type schema:CreativeWork
285 https://doi.org/10.1158/1078-0432.ccr-06-3093 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006258831
286 rdf:type schema:CreativeWork
287 https://doi.org/10.1158/1078-0432.ccr-08-2787 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033328549
288 rdf:type schema:CreativeWork
289 https://doi.org/10.1200/jco.1999.17.11.3461 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074545753
290 rdf:type schema:CreativeWork
291 https://doi.org/10.1200/jco.2007.12.4487 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031178629
292 rdf:type schema:CreativeWork
293 https://doi.org/10.1200/jco.2008.18.9159 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008720167
294 rdf:type schema:CreativeWork
295 https://doi.org/10.2217/fon.09.36 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006149341
296 rdf:type schema:CreativeWork
297 https://doi.org/10.3390/ph3092751 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000403597
298 rdf:type schema:CreativeWork
299 https://doi.org/10.3816/cgc.2005.n.015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012400722
300 rdf:type schema:CreativeWork
301 https://doi.org/10.4161/epi.3.6.7273 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072302870
302 rdf:type schema:CreativeWork
303 https://www.grid.ac/institutes/grid.14003.36 schema:alternateName University of Wisconsin–Madison
304 schema:name Paul P. Carbone Cancer Center, University of Wisconsin, Madison, WI, USA
305 rdf:type schema:Organization
306 https://www.grid.ac/institutes/grid.248762.d schema:alternateName BC Cancer Agency
307 schema:name British Columbia Cancer Agency, Kelowna, BC, Canada
308 British Columbia Cancer Agency, Vancouver, BC, Canada
309 rdf:type schema:Organization
310 https://www.grid.ac/institutes/grid.418424.f schema:alternateName Novartis (United States)
311 schema:name Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
312 rdf:type schema:Organization
313 https://www.grid.ac/institutes/grid.419481.1 schema:alternateName Novartis (Switzerland)
314 schema:name Novartis Pharma AG, Basel, Switzerland
315 rdf:type schema:Organization
316 https://www.grid.ac/institutes/grid.4367.6 schema:alternateName Washington University in St. Louis
317 schema:name Siteman Cancer Center, Barnes-Jewish Hospital, Washington University School of Medicine, St. Louis, MO, USA
318 rdf:type schema:Organization
319 https://www.grid.ac/institutes/grid.51462.34 schema:alternateName Memorial Sloan Kettering Cancer Center
320 schema:name Memorial Sloan-Kettering Cancer Center, New York, NY, USA
321 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...